Guggenheim analyst Michael Schmidt lowered the firm’s price target on enGene (ENGN) to $27 from $30 and keeps a Buy rating on the shares after the company reported Q1 earnings and announced plans to report an additional LEGEND Phase 2 study interim analysis at a spring 2026 medical conference.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- Buy Rating on enGene: Detalimogene’s Competitive Efficacy, Community-Friendly Delivery, and Regulatory Momentum Support $25 Target
- enGene Strengthens Balance Sheet as Bladder Cancer Gene Therapy Nears Key 2026 Milestones
- enGene reports Q1 EPS (44c), consensus (57c)
- enGene to Highlight Genetic Medicine Pipeline at Series of Investor Conferences
- enGene files $400M mixed securities shelf